Login
GenesisCare sold to consortium
Several firms have advised on the sale of a significant equity stake in Australia’s largest provider of radiation oncology, cardiology and sleep treatments, GenesisCare.
Emma Musgrave
Firms: Herbert Smith Freehills (GenesisCare Limited); King & Wood Mallesons (GenesisCare Limited); DLA Piper (KKR); Allen & Overy (China Resources); Corrs Chambers Westgarth (Macquarie Group consortium)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: GenesisCare has been advised on the sale of a significant equity stake in the company to a consortium comprising China Resources and Macquarie Group.
The transaction involved the exit of private equity firm KKR from its 45 per cent equity stake in Genesis Care – held since 2012.
Value: Approximately $1.7 billion
Area: Finance, M&A
Key players: The Herbert Smith Freehills team advising Genesis Care was led by partner Stephen Dobbs and senior associate Alexandra Sweeney, with assistance from partner Peter Dunne and senior associates Sami Wilson and Jonathan Wood.
Assistance in respect of GenesisCare’s UK operations was provided by Chris Gill from Herbert Smith Freehills’ London office.
Deal significance: GenesisCare is Australia's largest provider of radiation oncology, cardiology and sleep treatments.
It has also recently expanded its operations into the UK – where it is the largest private radiotherapy provider – and Spain.
The transaction reinforces healthcare as a sector with significant attraction for investors. It also provides a platform for GenesisCare to export world-leading Australian healthcare expertise into China and other overseas markets.
The structure of this deal was complex as a result of GenesisCare’s unique equity structure, according to HSF partner Stephen Dobbs (pictured).
Mr Dobbs said the broader arrangements involved doctors and management having the opportunity to sell down part of their holdings alongside KKR’s exit, which required formal shareholder consents and approvals to be obtained.
Other key conditions included FIRB approval, which was obtained approximately three months after the transaction was announced.
“It is fantastic to have been on the GenesisCare team once again as the business reaches another major strategic milestone,” said Mr Dobbs.
“We have been involved with GenesisCare since its inception in 2004, and we greatly appreciate the faith that the company has placed in us over that time.
“It is an inspiring business run by inspiring people, and we very much look forward to the next phase.”
